Please login to the form below
BeiGene
This page shows the latest BeiGene news and features for those working in and with pharma, biotech and healthcare.
BeiGene gets speedy US review for lymphoma drug zanubrutinib
First US filing is major milestone for Chinese firm. Chinese biopharma company BeiGene has claimed priority review status for its BTK inhibitor zanubrutinib from the FDA, setting up a possible approval ... It’s a major milestone for BeiGene,
Latest news
-
Hansoh Pharma shares head skyward after HKEX debut
including BeiGene and WuXi AppTec, after changing regulations to allow companies without revenues or profits to list on the HKEX.
-
Chi-Med goes for third IPO in Hong Kong
Last August, BeiGene raised a whopping $903m in its HKEX debut, near the top of its target range, to help it fund its own portfolio of cancer drugs headed by
-
China’s BeiGene raises $903m from Hong Kong IPO
BeiGene recently said it had completed enrolment in a phase III trial of zanubrutinib in Waldenström macroglobulinemia and could file for approval in the US in mid-2019. ... BeiGene’s shares are expected to begin trading on the HKEX on 8 August under
-
Daily Brief: Biosimilars ready to pounce on Humira, Hong Kong could rival Nasdaq, Kymab's OX40 candidate
Read the NHS' internal briefing on adalimumab biosimilars from May. Hong Kong could be new biotech hub, says Beigene, heading for $1bn floatation. ... A total of eight companies in biotech research have filed since May, and now Beigene is planning the
-
Keytruda is first I-O drug cleared for melanoma in China
China’s pharma industry isn’t resting on its laurels, however, and Beijing company BeiGene said earlier this week it plans to file for approval of its PD-1 inhibitor tislelizumab
More from news
Approximately 6 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
Chinese biotech’s global ambitions
BeiGene says it as headed off any such concens by working with well-established pharma company and contract manufacturer Boehringer Ingelheim to manufacture its drug. ... Meanwhile, BeiGene is also looking to break into the still all-important US market.
-
Biopharma's Future: Made in China
The rise of Chinese biopharma. One home-grown pharma company which could replicate this accomplishment is Beijing-headquartered BeiGene. ... BeiGene’s CEO John Oyler told a Goldman Sachs recent conference that a Chinese biopharma sector was ready to
-
Deal Watch March 2017
In particular, the third largest deal of the month is a joint venture between the research-based biotechnology company, BeiGene, which focuses on immuno-oncology, and the Guangzhou Development District. ... The agreement, worth $330m, will build BeiGene
-
Deal Watch table for November 2013
BeiGene / Merck. Serono. Co-development. Expansion of collaboration to include BeiGene 290 for cancer.
More from intelligence
Approximately 2 fully matching, plus 2 partially matching documents found.
Featured jobs
- Account Director, Healthcare Communications
-
Salary TBC
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
-
Account Director – UK Office
-
Excellent salary and benefits
- FREELANCE Account Director – Healthcare Advertising – London – 3...
-
Competitive Daily Rates
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
Subscribe to our email news alerts
- Finch Therapeutics bags $53m for microbiome therapies
- MSD taps Austria’s Themis to bolster vaccine pipeline
- Early ‘no’ for GW Pharma’s epilepsy drug, but NICE vows to collaborate
- GSK preps filings for BCMA-targeting multiple myeloma drug
- Behaviour change – is there something missing?
- NICE’s long-serving chief exec Sir Andrew Dillon to step down
PMHub
COUCH.
WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...
Latest intelligence
- Empowered patients: shaking the foundations of healthcare
- Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
- A uniquely English genomic medicine service
- The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
- Blended Intelligence
- Data is the most valued commodity of the modern world. For P&P it's all about the application....
Quick links
Infographics
